KBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-5 (AOMT 2026-5)

KBRA assigned preliminary ratings to 10 classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-5, a $240.2 million non-prime RMBS deal backed by 458 residential mortgages. KBRA flags a meaningful concentration of “non-prime” collateral, with 59.0% of loans classified as non-qualified mortgages and 41.0% as exempt from Ability-to-Repay/Qualified Mortgage requirements. Overall impact appears limited to credit/risk assessment at this stage, as this is preliminary rating coverage.

Analysis

This is more a funding-market read than a credit event. For AOMR, the real variable is whether the securitization market is still willing to finance non-QM collateral at a cost of capital that leaves residual economics intact; preliminary ratings alone do not tell us that, but they do signal that the channel remains open. If final execution comes in tight, the near-term winners are the originators/aggregators with inventory to move and warehouse lines to recycle; if execution is loose, the pain shows up first in margin compression, then in slower advance rates and tighter underwriting across the non-agency stack.

The second-order effect is on competitive behavior: stable private-label takeout tends to encourage more loan production from non-bank lenders, which can steal share from agency-centric players only at the margin, while more likely pressuring smaller originators that rely on securitization windows rather than balance-sheet flexibility. The important risk is not default performance today, but whether investors start demanding more credit enhancement on the next few deals; that would reduce ROE for AOMR and could force a shift toward more retention or lower leverage over the next 1-3 months.

Contrarian take: the market may be overconfident that any successful issuance is a clean positive for the space. A healthy pipeline can also mean tighter spreads and more competition for collateral, which narrows economics even as volume improves. The catalyst to watch is final pricing versus recent non-QM comps and any change in warehouse or repo terms; if spreads widen materially or book value guidance softens, the thesis flips from 'funding is open' to 'capital is getting more expensive' within one quarter.

Key Decisions for Investors

• No immediate standalone trade in AOMR on the preliminary-rating headline; wait for final pricing and spread vs. recent non-QM comps before sizing exposure. Treat as a funding-window check, not an earnings catalyst.
• If the deal prices inside comparable non-QM RMBS by >25-50 bps, buy AOMR for a 1-3 month trade on improved securitization optionality; risk/reward is acceptable only if book value and leverage stay stable.
• If final execution is meaningfully wider than comps or the deal requires heavier credit enhancement, fade AOMR and reduce exposure to other non-agency lenders with similar warehouse dependence; that outcome would imply margin pressure over the next quarter.
• Set an alert on AOMR for any management commentary about warehouse advance rates, retained gain-on-sale, or securitization throughput in the next earnings call; those are the metrics that would confirm or falsify the thesis.